SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Official Title

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)


This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

Trial Description

Primary Outcome:

  • Overall survival (OS)
Secondary Outcome:
  • Cognitive failure-free survival (CFFS)
  • CFFS rate
  • Cumulative incidence of cognitive failure
  • OS in an "as-treated" analysis
  • Brain metastases-free survival (BMFS)
  • Incidence of adverse events
  • To evaluate whether overall survival (OS) with magnetic resonance imaging (MRI) surveillance alone is not inferior to MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).
  • To compare cognitive failure free survival (CFFS) rate up to 12 months after randomization between the arms.
  • To compare brain-metastasis-free survival between the arms.
  • To compare OS between the arms within the subgroups of patients with limited-stage and extensive-stage disease.
  • To compare cognitive failure free survival (CFFS) rates at the assessment times between the arms.
  • To compare the cumulative incidence of cognitive failure with death as a competing risk between the arms.
  • To compare the frequency and severity of toxicities between the two arms.
  • To collect blood for banking.
Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
ARM II: Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society